International Journal of Scientific Research in Engineering and Management (IJSREM)
Volume: 07 Issue: 08 | August - 2023 SJIF Rating: 8.176 ISSN: 2582-3930

NANOPARTICLE BASED DRUG DELIVERY SYSTEMS FOR TARGETING TUMOR MICRO ENVIRONMENT

Krithika K, Nikita Bagade, Yeshaswini Radhakrishnan, Dr.Praveen Kumar Gupta
Department of Biotechnology,
R V College of engineering, Bangalore, India

Abstract

Nanoparticle-based drug delivery systems have emerged as promising tools in cancer therapy, offering enhanced precision and effectiveness in targeting tumor cells while minimizing damage to healthy tissues. This review provides a comprehensive exploration of the tumor microenvironment, emphasizing its critical role in cancer progression. It highlights the significance of targeted drug delivery in improving treatment outcomes and introduces nanoparticle-based delivery systems as innovative strategies to address these challenges.

The first section delves into various types of nanoparticles used for tumor targeting. Liposomes, known for their versatility and biocompatibility, are discussed alongside examples of liposome-based drug delivery systems tailored for tumor-specific applications. Polymeric nanoparticles, employing a range of polymers, offer unique advantages and applications in tumor targeting. Metallic nanoparticles, with distinctive properties, have shown promise in drug delivery systems designed to target tumors effectively.

The design considerations for tumor targeting form the core of the third section. Passive targeting exploits the Enhanced Permeability and Retention (EPR) effect, and strategies to enhance this approach using nanoparticles are explored. Active targeting methods, involving ligand-mediated and biomarker-specific approaches, are detailed. Additionally, combination strategies and stimulus-responsive drug release systems are examined for their potential synergistic effects in improving tumor targeting.

The challenges and opportunities associated with nanoparticle-based drug delivery systems are outlined in the fourth section. Overcoming physiological barriers, optimizing drug release kinetics, and ensuring safety and biocompatibility are key concerns addressed in this section. Strategies to bypass systemic clearance and immune responses, achieve controlled drug release, and enhance biocompatibility are discussed in depth.

The review also delves into clinical applications and future directions, highlighting examples of successful nanoparticle-based drug delivery systems in preclinical and clinical studies. Challenges in

translating research to clinical practice are acknowledged, paving the way for a discussion on emerging technologies and future perspectives. Advances in nanotechnology, coupled with potential areas for further research, underscore the exciting prospects for nanoparticle-based drug delivery systems in cancer treatment.

In conclusion, this review synthesizes the intricate landscape of nanoparticle-based drug delivery systems for tumor targeting. It emphasizes the substantial progress made in this field, showcasing its potential to revolutionize cancer therapy. As the research landscape continues to evolve, nanoparticle-based drug delivery systems hold the promise of reshaping the future of cancer treatment through their precise and efficacious targeting capabilities.

1. Introduction

Cancer, a prevalent and significant ailment worldwide, imposes a substantial burden on both health and economies. The complexities of cancer emanate from an array of genetic and epigenetic changes that confer distinct attributes upon cancer cells, bestowing them with traits such as unchecked growth, evading cell death, invasiveness, resistance to immunity, unlimited replication, and the ability to metastasize. However, it's not just the genetic alterations within cancer cells that define the disease; the interplay between cancer cells and the non-cancerous stromal elements within the tumor microenvironment plays an equally vital role in shaping the course of tumor progression.

Within the intricate tapestry of cancer, a dynamic interaction unfolds among an assortment of cellular components, including cancer cells, stromal cells, and the extracellular matrix (ECM). The stroma, traditionally recognized as a scaffolding for healthy tissue, acquires a distinct role in the context of cancer by offering indispensable support and resources that fuel the relentless growth of cancer cells. Deciphering the contributions of individual stromal constituents in the realm of carcinogenesis holds the promise of providing crucial insights into cancer diagnosis and therapeutic strategies.

Fueling the voracious appetite of tumor cells for nutrients and oxygen is the intricate network of blood vessels. These vessels not only act as conduits for nourishment but also serve as gateways for immune cells and other circulating elements. The heightened demand for sustenance within tumor cells drives the phenomenon of angiogenesis, ensuring an incessant supply of nutrients that fuels their uncontrolled proliferation.

The establishment of a well-functioning vascular network is pivotal for tissue health and growth. This intricate network relies on a delicate balance of growth factors, vascular cells, and non-vascular components. However, this equilibrium is perturbed in the context of cancer, giving rise to a structurally and functionally distinct tumor vasculature.

In addition to neoplastic cells, tumors encompass a mosaic of non-cancerous components, encompassing fibroblasts, endothelial cells, and immune cells, collectively known as the tumor stroma. This dynamic ecosystem significantly influences tumor development, orchestrating processes like tumor vascularization that profoundly impact metastatic potential. Recent revelations highlight the tumor microenvironment's role in shaping responses to therapies, underscoring its importance as a therapeutic target. Manipulating the tumor stroma presents an innovative avenue for augmenting treatment efficacy and devising novel therapeutic approaches.

The tumor stroma encompasses a plethora of critical elements, including immune cells, vascular cells, mesenchymal support cells (such as fibroblasts and adipocytes), and the ECM enveloping cancer cells. Beyond cellular constituents, the stroma is a reservoir of signaling molecules, including growth factors, cytokines, chemokines, and antibodies. This comprehensive exploration seeks to delve into the intricate dance of stromal elements and their contributions to key processes such as angiogenesis, tumor progression, and invasion. Gaining a deeper understanding of how these components influence various facets of tumor biology holds promise for refining diagnostic and prognostic strategies and fostering the development of innovative therapeutic interventions targeting the tumor microenvironment.

Cancer is a significant cause of compromised quality of life and mortality. The intricate molecular events in cancer have made it a focal point of research for academic, industrial, and non-profit institutions, such as the National Cancer Institute (NCI), the European Organization for Research and Treatment of Cancer (EORTC), and the British Cancer Research Campaign (CRC). Traditional cancer drug therapy focused on cytotoxic compound identification, often with high dose-limiting toxicities and a narrow therapeutic range, necessitating close-to-maximum dosing. Targeted drug delivery to tumor sites aims to enhance efficacy and reduce toxicity. This requires an understanding of cancer's pathophysiology.

Tumors result from uncontrolled cell proliferation, demanding metabolic substrates and waste removal. Early tumor growth relies on surrounding tissue vasculature, but it must establish its own blood supply as it exceeds a critical size. Tumor vasculature development is disorderly, differing from normal tissue vasculature. Tumor vascular architecture's therapeutic significance lies in its potential manipulation for cancer treatment and targeted drug delivery. For instance, irregular intervessel distances and abnormal reactivity of tumor microcirculation can be exploited for therapeutic approaches like radio-sensitizers and hyperthermia, utilizing factors like hypoxia or proliferation gradients.

While many reviews discuss tumor physiology and drug delivery, the specific role of tumor vascular architecture was last

comprehensively explored over a decade ago, within a limited scope. This paper delves into tumor vascular architecture's development, characteristics, facilitation and hindrance of targeted drug delivery, and its impact on drug therapy for cancer.**[1 and 2]**

2. Types of Nanoparticles for Tumor Targeting

Various types of nanoparticles, such as liposomes, polymeric micelles, dendrimers, superparamagnetic iron oxide crystals, and colloidal gold, have been employed in targeted therapies for cancer. Both passive and active targeting strategies can be utilized for nano drug delivery. Passive targeting is based on the enhanced permeability and retention (EPR) effect of the vasculature surrounding tumors. Active targeting relies on ligand-directed binding of nanoparticles to receptors expressed by tumor cells. Release of loaded drugs from nanoparticles may be controlled in response to changes in environmental condition such as temperature and pH. Biodistribution profiles and anticancer efficacy of nano-drugs in vivo would be different depending upon their size, surface charge, PEGylation and other biophysical properties.The following are a few commonly used methods. **[10]**



Fig 1: Types of nanocarriers for targeted drug delivery.**[9]**

A.Liposome mediated:

The discovery of liposome or lipid vesicles emerged from self forming enclosed lipid bi-layer upon hydration; liposome drug delivery systems have played a significant role in formulation of potent drugs to improve therapeutics. Recently the liposome formulations are targeted to reduce toxicity and increase accumulation at the target site. There are several new methods of liposome preparation based on lipid drug interaction and liposome disposition mechanisms including the inhibition of rapid clearance of liposome by controlling particle size, charge and surface hydration. Most clinical applications of liposomal drug delivery are targeting tissue with or without expression of target recognition molecules on lipid membrane. The liposomes are characterized with respect to physical, chemical and biological parameters. The sizing of the liposome is also a critical parameter which helps characterize the liposome and is usually performed by sequential extrusion at relatively low pressure through polycarbonate membrane (PCM).

Advantages:

Liposomes are synthetic lipid vesicles that can encapsulate a wide range of therapeutic agents, including small molecules, proteins, nucleic acids, and nanoparticles. They have several properties that make them attractive for drug delivery.This mode of drug delivery lends more safety and efficacy to administration of several classes of drugs like antiviral, antifungal, antimicrobial, vaccines, anti-tubercular drugs and gene therapeutics.

Biocompatibility: Liposomes are generally well tolerated by the body and can be designed to minimize immune responses and toxicity.

Encapsulation capacity: Liposomes can encapsulate both hydrophilic and hydrophobic drugs, providing versatility in drug loading.

Targeting capability: By modifying the liposome surface with ligands or antibodies specific to TME-associated biomarkers, liposomes can be engineered to selectively recognize and bind to tumor cells or the surrounding microenvironment



Fig 2: Liposomal mediated drug delivery **[9]**

Applications:

Present applications of the liposomes are in immunology, dermatology, vaccine adjuvant, eye disorders, brain targeting, infective disease and in tumor therapy.

It plays a critical role in tumor growth, invasion, and metastasis.The new developments in this field are the specific binding properties of a drug-carrying liposome to a target cell such as a tumor cell and specific molecules in the body (antibodies, proteins, peptides etc.); stealth liposomes which are especially being used as carriers for hydrophilic (water soluble) anticancer drugs like doxorubicin, mitoxantrone; and bisphosphonate- liposome mediated depletion of macrophages.

Example:

Most of the liposomal- or lipid-based formulations or therapeutic molecules are linked to polyethylene glycol (PEG).One such product is PEGylated liposomal doxorubicin, which is known as Doxil in the US and Caelyx in Europe**[5].** It is being used to treat the Kaposi's sarcoma that is associated with AIDS.It is seen that the use of Liposomes to carry doxorubicin has increased its efficiency.

B.Polymeric nanoparticles

Nanoparticles, on the other hand, can be incorporated into liposomes to enhance the drug delivery system's performance..Polymeric nanoparticles are tiny particles made from biocompatible and

biodegradable polymers. They can encapsulate therapeutic drugs and deliver them directly to tumor sites, making them an effective drug delivery system for cancer treatment. By utilizing passive accumulation through the Enhanced Permeability and Retention (EPR) effect and active targeting with specific ligands, polymeric nanoparticles enhance drug delivery to tumor cells while minimizing harm to healthy tissues.

Advantages:

Nanoparticles offer unique properties, such as tunable size, high surface area, and potential for multifunctionality. When combined with liposomes, they can improve drug encapsulation efficiency, stability, and controlled release

Size and Surface Properties: Nanoscale size (10-200 nanometers) allows passive accumulation in tumor sites, and surface modifications enable active targeting by binding to tumor-specific receptors.

Protection of Drugs:Polymeric nanoparticles shield drugs from degradation in the bloodstream, enhancing stability and bioavailability.

Overcoming Multidrug Resistance (MDR): Nanoparticles can bypass MDR pumps, ensuring drug delivery inside resistant tumor cells.

Enhanced Drug Efficacy:Targeted drug delivery concentrates therapeutic agents in tumors, improving treatment outcomes.

Versatility and Tunability:Nanoparticle properties can be customized to optimize drug release, targeting, and circulation time.

Example :

Cyclodextrins (CDs) are one of the most extensively studied cyclic-oligosaccharides due to their low toxicity, good biodegradability and biocompatibility, facile chemical modification, and unique inclusion capacity. **[7]** Recent studies have shown that ,by adding polymers to it, its efficiency in treating cancer increases.

C.Metallic Nanoparticles:

Metallic nanoparticles are nanoscale particles made from various metals, such as gold, silver, iron oxide, or platinum. They have unique properties, making them promising candidates for drug delivery and imaging applications in cancer treatment. Metallic nanoparticles can be engineered to deliver drugs to tumor sites, enhancing therapeutic outcomes, and enable precise imaging for diagnosis and monitoring of treatment response.

Advantages:

Size and Surface Properties: Metallic nanoparticles are typically in the nanometer size range, enabling passive accumulation in tumors through the EPR effect. Their surfaces can be modified with targeting ligands for active tumor recognition.

Drug Loading Capacity:
Metallic nanoparticles can carry a high payload of drugs due to their large surface area, allowing for efficient drug delivery.

Photothermal and Radiotherapy Properties:Some metallic nanoparticles, like gold nanoparticles, possess photothermal and radiotherapy capabilities, providing additional therapeutic benefits through localized heat generation or enhanced radiation dose delivery to tumors.

Imaging Contrast Agents:Metallic nanoparticles exhibit strong contrast in various imaging modalities, including CT, MRI, and optical imaging, facilitating non-invasive tumor detection and monitoring of drug delivery.

In conclusion, metallic nanoparticles offer unique advantages for drug delivery, imaging, and combination therapies in cancer treatment. Their tunable properties, high drug-loading capacity, and imaging capabilities make them a promising tool to enhance precision medicine approaches in targeting the tumor microenvironment. However, careful consideration of biocompatibility and potential long-term toxicity is essential when designing metallic nanoparticle-based therapies.

Example: AuNPs conjugated with various drugs like TMZ, cisplatin created a remarkable concept that increased several interests, especially for their binding property with a wide range of organic and biological molecules, their low toxicity and robust absorption spectrum.**[8]**

3. Design Considerations for Tumor Targeting

A. Passive Targeting

Enhanced Permeability and Retention (EPR) Effect:

The EPR effect is a unique characteristic of tumor vasculature. Tumor blood vessels are often leaky and have poor lymphatic drainage, allowing nanoparticles to passively accumulate in the tumor microenvironment **[6].** The leaky blood vessels allow nanoparticles to escape into the tumor interstitium, while impaired lymphatic drainage prevents their efficient clearance. This phenomenon leads to enhanced retention of nanoparticles in the tumor region.



Fig 3: Fate of a passively targeted drug **[6]**

Strategies to Enhance Passive Tumor Targeting using Nanoparticles:

To maximize passive targeting, nanoparticle design can be optimized:

Size:Nanoparticles with sizes within the optimal range of 10-200 nanometers tend to accumulate more efficiently in tumor tissues.

Surface Properties: Hydrophilic surface coatings can reduce nonspecific interactions with blood components and extend circulation time, increasing the chances of reaching the tumor site.

Long Circulation:Prolonged circulation of nanoparticles can enhance EPR-mediated tumor accumulation due to increased opportunities for extravasation into the tumor.

Shape: Certain nanoparticle shapes (e.g., spherical) have shown improved EPR-based targeting compared to others.

B. Active Targeting

Ligand-Mediated Targeting Approaches:

Active targeting involves attaching specific ligands (such as antibodies, peptides, or aptamers) to the surface of nanoparticles. These ligands have high affinity and specificity for tumor-associated receptors or antigens. When nanoparticles with targeting ligands are administered, they bind to these receptors on tumor cells, promoting selective internalization and enhanced cellular uptake of nanoparticles at the tumor site.

Targeting Specific Tumor-Associated Biomarkers:

Various tumor-associated biomarkers, such as overexpressed receptors or antigens, are unique to certain cancer types or subtypes. By identifying and utilizing these specific biomarkers, nanoparticles can be functionalized with corresponding targeting ligands, tailoring the delivery system to the tumor's molecular characteristics.

C. Combination Strategies

Dual-Targeting Approaches:

Dual-targeting involves the incorporation of multiple ligands on the nanoparticle surface, enabling both passive and active targeting simultaneously. This approach leverages the advantages of EPR-mediated passive targeting and ligand-mediated active targeting to increase nanoparticle accumulation and cellular uptake within the tumor microenvironment.

Stimulus-Responsive Drug Release Systems:

Stimulus-responsive drug release systems are designed to release drugs in response to specific triggers present in the tumor microenvironment. These triggers can include pH variations, enzymes, temperature changes, or other factors characteristic of the tumor. By incorporating stimuli-sensitive materials, nanoparticles can release drugs selectively at the tumor site, improving drug efficacy and reducing off-target effects.

In summary, the design considerations for tumor targeting with nanoparticles involve both passive and active targeting strategies. Passive targeting takes advantage of the EPR effect, while active targeting involves ligand-mediated approaches to specifically

recognize tumor-associated biomarkers. Combination strategies use dual-targeting to maximize tumor accumulation, and stimulus-responsive drug release systems ensure precise drug delivery at the tumor site. These design considerations allow for the development of highly efficient and selective nanoparticle-based drug delivery systems for improved cancer treatment outcomes.

Characteristics and advantages for drug delivery

To develop liposome-mediated nanoparticle-based drug delivery systems for targeting the TME, researchers employ various strategies:

1. Surface modification: Liposomes can be modified with ligands, antibodies, or peptides that specifically recognize receptors or antigens overexpressed in the TME. This modification allows for enhanced tumor cell targeting and internalization.

2. Enhanced permeability and retention (EPR) effect: Liposomes can exploit the leaky vasculature and impaired lymphatic drainage commonly found in solid tumors. This phenomenon, known as the EPR effect, allows liposomes to accumulate selectively within the tumor tissue.

3. Stimuli-responsive release: Liposomes can be engineered to respond to specific TME conditions, such as pH, temperature, or enzymatic activity. This enables controlled release of the therapeutic payload within the tumor microenvironment, enhancing efficacy while minimizing off-target effects.

4. Combination therapies: Liposome-mediated nanoparticle-based drug delivery systems can incorporate multiple therapeutic agents, such as chemotherapeutic drugs, immunomodulators, or gene therapies, to create synergistic effects against tumors and their microenvironment.

Overall, liposome-mediated nanoparticle-based drug delivery systems provide a versatile platform for targeted drug delivery to the tumor microenvironment. Continued research and development in this field hold significant promise for improving cancer treatment outcomes by enhancing therapeutic efficacy and minimizing systemic side effects.

Mechanism of action:

The mechanism of action of liposome-mediated nanoparticle-based drug delivery systems for targeting the tumor microenvironment involves several steps:

1. Targeting: Liposomes are modified with ligands, antibodies, or peptides that specifically recognize and bind to biomarkers or receptors overexpressed in the tumor microenvironment. This targeting moiety enables selective accumulation and binding of liposomes to tumor cells or components of the TME.

2. Uptake and internalization: Once the liposomes have bound to their target in the

TME, they can be internalized by tumor cells through various endocytic mechanisms, such as receptor-mediated endocytosis or phagocytosis. The liposomes can also passively enter the tumor cells due to their small size and the presence of leaky vasculature in the tumor tissue.

3. Intracellular drug release: After internalization, liposomes are typically trafficked to the endosomal/lysosomal compartments within the tumor cells. In some cases, the low pH environment of the endosomes/lysosomes triggers the destabilization and rupture of the liposomes, leading to the release of the encapsulated therapeutic agents into the cytoplasm.

4. Tumor microenvironment interactions: Liposomes can interact with various components of the tumor microenvironment beyond tumor cells. They can come into contact with cancer-associated fibroblasts, immune cells, extracellular matrix components, and signaling molecules present in the TME. These interactions can influence the release, distribution, and efficacy of the therapeutic agents within the tumor microenvironment.

5. Controlled drug release: Some liposome formulations can be designed to respond to specific stimuli present in the tumor microenvironment, such as the acidic pH, high levels of enzymes, or elevated temperatures. These stimuli can trigger liposome destabilization or membrane fusion events, resulting in controlled and targeted release of the encapsulated drugs within the tumor microenvironment.

6. Therapeutic effect: Once released from the liposomes, the therapeutic agents can exert their intended pharmacological effects on the tumor cells or components of the TME. These effects may include cytotoxicity, inhibition of tumor growth, modulation of the immune response, or alteration of the tumor microenvironment to enhance treatment efficacy.

By utilizing the properties of liposomes and nanoparticles in combination with targeted ligands, the drug delivery system can enhance the accumulation of therapeutic agents within the tumor microenvironment, increase cellular uptake, and provide controlled and localized drug release. This approach aims to improve the therapeutic efficacy of anticancer drugs while minimizing off-target effects, leading to more effective cancer treatment strategies.

4. Challenges and Opportunities

A. Physiological barriers

An additional hurdle that nanoparticles encounter in their role as drug delivery systems (DDSs) for cancer treatment involves the intricate web of physiological barriers that separate them from their ultimate target – tumor cells. When administered systemically, nanoparticles embark on a complex journey, traversing microvessel walls, navigating through the extracellular matrix, and breaching the plasma membrane of cells to facilitate drug

delivery. However, each of these stages presents its own distinct set of challenges, impeding nanoparticle transport through disruptions in transvascular, interstitial, and transmembrane pathways .

The phenomenon known as the enhanced permeability and retention (EPR) effect often comes into play within tumors, where leaky vasculature allows nanoparticles to accumulate preferentially. Nevertheless, this picture is not without nuances, as certain regions within tumors may exhibit low or even impermeable microvessels, creating a landscape of heterogeneity in nanoparticle distribution. This intricate interplay between vasculature characteristics further complicates the accurate and uniform delivery of nanoparticles.

Having surmounted the challenge of microvessel penetration, nanoparticles then confront another hurdle upon entering the interstitial space within solid tumors. Here, the environment offers limited convective transport driving forces, rendering nanoparticle movement less efficient. This reduced mobility within the densely packed tumor environment can hamper the uniform dispersion of nanoparticles, potentially leading to their accumulation primarily in the perivascular and peripheral regions of the tumor .

In summary, the journey of nanoparticles within the context of cancer treatment is marked by a series of formidable physiological barriers. These obstacles range from overcoming the intricate network of microvessels and extracellular matrix to navigating through the cellular membrane. While the EPR effect aids in nanoparticle accumulation within tumors, the presence of impermeable microvessels and limited convective transport within the tumor microenvironment introduce complexities that can result in uneven distribution. These challenges underscore the need for innovative strategies to enhance nanoparticle penetration and distribution, ultimately optimizing their efficacy as potent drug delivery systems in the fight against cancer.**[3]**

B. Drug Development Kinetics

In the realm of nanoparticle (NP) research, the interplay between NP properties like size, shape, and surface charge and their impact on efficacy and potential toxicity has been the subject of extensive exploration. However, a significant aspect that has not received comprehensive investigation in vivo is the influence of controlled drug release on NP effectiveness and safety. This study seeks to address this gap in knowledge from a third-person perspective.

A central challenge in unraveling the intricate relationship between drug release dynamics and therapeutic outcomes lies in devising NPs that exclusively vary in their drug release profiles while maintaining uniformity in all other NP attributes. To overcome this hurdle, the researchers have innovatively developed crosslinkable lipid shell (CLS) NPs. These CLS NPs offer the unique advantage of enabling modulation of drug

release kinetics without inducing alterations in any other NP characteristics.

Within this context, the study's primary goal is to establish a direct correlation between drug release kinetics and the therapeutic efficacy and potential toxicity of NP-delivered drugs. By utilizing CLS NPs loaded with model drugs such as wortmannin and docetaxel, the researchers aim to elucidate how the kinetics of drug release influence the performance of these drugs both in controlled laboratory settings and within living organisms.

The study's findings thus far have revealed that indeed, the kinetics of drug release play a pivotal role in dictating the therapeutic effectiveness of NP docetaxel and NP wortmannin. This effect holds true across in vitro experiments as well as in vivo scenarios. Notably, the investigation has also underscored that a reduction in drug release kinetics can lead to a concurrent reduction in the hepatic toxicity associated with CLS NP wortmannin.

This pioneering research offers a crucial insight – supported by the utilization of two representative drugs – that the specific drug release profile of NPs significantly impacts their efficacy and safety within living systems. In essence, the study sheds light on a critical determinant that shapes the therapeutic potential of NPs and their implications for clinical applications.**[4]**

5. Clinical Applications and Future Directions:

There are several reasons for employing nanoparticles for therapeutic and diagnostic agents and advancement of drug delivery in clinical practices. One of them is that traditional drugs available now for oral or injectable administration are not always manufactured as the optimal formulation for each product. Protein or Nucleic acid containing products require a more innovative type of carrier system in order to improve their efficacy and protect them from degradation.

Owing to their small size and large surface area, drug nanoparticles display increased solubility, thereby enhancing bioavailability, additional ability to cross the blood brain barrier (BBB), and enter the pulmonary system.

A. Cancer Therapy:

Current chemotherapy is mainly aimed at destroying all rapidly dividing cells. Despite being effective in destroying cancerous cells, the body’s other rapidly proliferating cells, such as in the hair follicles and intestinal epithelium are also destroyed, leaving patients to endure life changing side effects. The development of nanoparticles has provided a new avenue for chemotherapy. With the discovery of smartly designed nanoparticles, targeted drug delivery at the tumor site largely avoids the toxic effects that other normal tissues and organs could be susceptible to.

Micelles and liposomes offer an effective option for delivery of chemotherapeutic

agents. Micelles also effectively make insoluble drugs soluble as they possess a hydrophobic core and a hydrophilic shell. If the micelle's surface is further PEGylated, it increases the ability of the nanocarriers to get through fenestrated vasculature of tumors and inflamed tissue through passive transport, thus resulting in higher drug concentration in tumors.

While there are several other forms of nanoparticles that have shown promise in cancer treatment, one of the most recent systems is the carbon nanotubes. Carbon nanotubes (CNTs) is an allotropic form of carbon with cylindrical framework and deepening on number of sheets in concentric cylinders, they can be classified as single-walled carbon nanotubes (SWCNTs) and multiwalled carbon nanotubes (MWCNTs).

B. Chemotherapy Delivery:

The most significant application of nanotechnology today is nano-oncology, the use of nano-biotechnology in the treatment of cancer. Drug bioavailability, solubility, biodistribution, drug elimination from treatment-induced drug resistance, and nonspecific toxicity can all be improved by the creation of nanoparticles chemotherapeutic drug delivery systems based on nanotechnology. In particular, it can improve patients' quality of life, lengthen patients' survival times, and lessen the undesired side effects that chemotherapy causes in patients. According to several recent studies, nanoparticles can infiltrate cells, tissues, and organs that bigger size particles typically cannot, penetrate biofilms, and deliver medications to areas that are challenging for conventional chemotherapy drugs to reach. Nanoparticles can improve the delivery of conventional chemotherapeutic drugs by enhancing their stability, solubility, and tumor-specific targeting. This targeted delivery reduces systemic toxicity and enhances the accumulation of drugs in the tumour, leading to improved treatment outcomes.

C. Photodynamic Therapy (PDT):

Nanoparticles can be loaded with photosensitizers for PDT. When exposed to light of a specific wavelength, these photosensitizer-loaded nanoparticles generate reactive oxygen species, leading to localized tumor cell destruction. The major advantage of photodynamic therapy is its selectivity in destroying target cells. The photosensitizer accumulates in the diseased or abnormal tissue, and the light exposure is localized to the target area. As a result, PDT minimizes damage to healthy surrounding tissues, reducing side effects and preserving organ function. Photodynamic therapy has been used to treat various types of cancer, including skin cancer (such as basal cell carcinoma and squamous cell carcinoma), lung cancer, esophageal cancer, and certain types of head and neck cancers. It is especially useful in cases where conventional treatments like surgery or radiation therapy may not be feasible or may cause significant cosmetic or functional damage. It causes minimal damage to healthy tissues, leading to fewer systemic side effects compared to traditional cancer treatments like chemotherapy.

D. Radiotherapy Enhancement:

The practice of enhancing the effects of radiation therapy on cancer cells by utilizing particular drugs or techniques is referred to as radiotherapy enhancement, also known as radiosensitization. The purpose of radiotherapy enhancement is to make cancer cells more sensitive to radiation, which improves tumor management while causing the least amount of harm to nearby healthy tissues. Nanoparticles can enhance the effectiveness of radiotherapy by increasing the local radiation dose to tumor cells. Radiosensitizing nanoparticles can improve tumor cell sensitivity to radiation, reducing the overall radiation dose required for treatment. Some medications or substances can make cancer cells more sensitive to radiation. These radiosensitizers may impede DNA repair processes and raise tumor oxygen levels or enhance the production of reactive oxygen species (ROS) when exposed to radiation, leading to increased DNA damage and cell death. It also acts as DNA repair inhibitors as cancer cells may activate DNA repair pathways after exposure to radiation, reducing the effectiveness of treatment. Inhibitors of DNA repair enzymes can block these repair processes, leading to increased radiation-induced DNA damage and tumor cell death.

E. Theranostics:

Nanoparticles with combined therapeutic and diagnostic capabilities, known as theranostics, offer a personalized approach to cancer therapy. They can deliver therapies while simultaneously providing imaging feedback, enabling clinicians to tailor treatment strategies based on real-time patient responses. Theranostic agents are designed to have two distinct functions. Not only can they carry therapeutic payloads, such as chemotherapy drugs, radioisotopes, or gene therapies, for targeted treatment of diseases, but these agents also contain imaging components, such as fluorescent dyes, nanoparticles, or radioactive tracers, to facilitate non-invasive imaging and diagnosis. This enables image-guided therapy, where clinicians can monitor the distribution and accumulation of therapeutic agents in real-time which can help adjust treatment plans, ensuring optimal drug delivery to the tumor and avoiding damage to healthy tissues. By analyzing changes in tumor size, metabolism, and molecular markers, clinical technicians can evaluate the efficacy of the therapy early on and make informed decisions about adjusting treatment procedures. It enables early detection and precise localization of tumors, improving patient outcomes through timely and accurate diagnosis.

F.Challenges in developing nanoparticles for drug delivery:

Nanomedicines are likely to be three-dimensional constructs of multiple components with preferred spatial arrangements for their specific functions. So any minute changes in process, composition or structure can negatively affect the complex superposition of the components and have

undesirable consequences. Nanoparticle drug delivery systems pose many challenges before they can reach the clinic, starting with detailed characterization and successful manufacture of these complex constructs. Apart from the standard criteria for acceptable safety, efficacy and desirable characteristics applicable to most drugs, an ideal nanoparticle system to be employed for therapeutic uses must possess the following features:

Detailed understanding of critical components and their interactions

Identification of key characteristics and their relation to performance

Ability to replicate key characteristics under manufacturing conditions

Easy to produce in a sterile form

Ability to target or accumulate in the desired site of action by overcoming the restrictive biological barriers

Good in-use stability, easy to store and to administer

At present, there are no good in vivo models to predict the diverse behaviors of the many types of nanoparticles under investigation, so the development of nanoparticles with desirable properties has to rely on empirical evidence and extensive preclinical animal testing.

The biocompatibility of nanoparticles is crucial to avoid adverse effects on healthy tissues and organs. Some nanoparticles may produce toxicity or immunological reactions, resulting in unwanted side effects. Immunogenicity may result from the immunological reactions that nanoparticles cause in the body. Certain nanoparticle formulations may cause allergic responses or hypersensitivity in some individuals, which might impair how well they tolerate and respond to treatment. They may build up in organs other than the site of the target tumor, thereby poisoning other tissues. This non-targeted biodistribution may result in effects that are off-target and may narrow the therapeutic window. Nanoparticles that are eliminated via the kidneys or liver may have a negative impact on these organs, particularly in people who already have liver or kidney disease.

A crucial component of nanoparticle-based drug delivery systems is drug release control, which makes sure that therapeutic drugs are delivered at the proper time and place within the body. The effectiveness of treatment is increased, side effects are decreased, and the benefits of nanoparticle-based therapies are maximized with proper drug release management. The release kinetics of drugs from nanoparticles can vary depending on factors like nanoparticle degradation rate, drug loading capacity, and interactions with biological fluids. Achieving consistent and predictable release profiles is challenging. When the tumor microenvironment is heterogeneous, stimuli like pH, temperature, or enzyme levels can vary. The tumor mass may experience uneven medication release as a result of its heterogeneity. Some nanoparticle formulations may exhibit a burst release of drugs upon administration, which can lead to non-targeted drug distribution and potential toxicity to healthy tissues.

More innovative testing methods are constantly being developed and applied to the analysis of nanoparticles. The key parameters, as well as the overall stability of nanoparticles, should be tested with nanoparticles in solid form, in suspension, and in biological medium, and under accelerated conditions such as higher temperature to ensure the robust performance of nanoparticles. However, these tests may not be able to functionally differentiate between an "active" formulation and one that is "inactive" or "less active."

I. Future Perspectives:

Nanotechnology applied to cancer therapy has led to a new era of cancer treatment. Various types of nanoparticles, both organic and inorganic nanoparticles, are already being frequently used in the clinically treating several types of cancer. Increased research of several hybrid nanoparticles have generated curiosity and demonstrated improved delivery capabilities. More thorough research on the molecular traits of specific tumors will result in more focused directions for these medications. Additionally, developing hybrid nanoparticles that are better suited for cancer therapy and developing nanoparticles that use targeting moieties to more precisely target cancer cells need additional investigation. There has been ongoing research in developing new targeting ligands that improve the accumulation of nanoparticles and uptake within tumor tissues while minimizing off-target effects. This could further enhance the selectivity and efficacy of cancer therapy. Future nanoparticles could be customized to be more responsive to specific cues in the tumor microenvironment, like variations in pH, temperature, or enzyme activity. This feature could allow controlled and targeted release of the drug at the tumor site, enhancing the efficiency of treatment.

Customized nanomedicine: Researchers are focusing on developing nanoparticle-based therapeutics that are specifically tailored to each patient in light of the advent of precision medicine and genomic advancements. Based on a patient's unique tumour features and molecular profile, personalised nanomedicine may entail choosing the best nanoparticle type, drug combination, and dosage.

Multi-Modal Nanoparticles:
Future nanoparticles may be designed to carry multiple therapeutic agents, diagnostic probes, and targeting ligands simultaneously. These multi-modal nanoparticles can combine therapies and imaging capabilities in a single agent, allowing for a comprehensive approach to cancer diagnosis and treatment.

Immunotherapy: Immunotherapy and nanoparticle-based therapies together have the potential to improve the anti-tumor immune response. When immunomodulatory medicines are delivered directly to the tumour microenvironment via nanoparticle technology, the immune system and

therapeutic pharmaceuticals work in concert to benefit patients.

Although nanoparticles offer great potential, there are still challenges to address, such as toxicity concerns, manufacturing scalability, and long-term safety profiles. As research progresses, these challenges are likely to be addressed, leading to a more comprehensive integration of nanoparticles into cancer treatment strategies in the future.

The results from nanoparticle-based drug delivery for tumour targeting show its potential as a potent tool in cancer treatment, providing improved drug delivery effectiveness, fewer side effects, and improved therapeutic outcomes. Enhanced permeation and retention, active targeting of tumour sites and controlled drug delivery among other discoveries can provide further scope for future research in nanoparticle-based drug delivery. The development of cancer therapy alternatives will likely be aided by the emergence of increasingly complex and potent nanoparticle-based medicines as research advances. Advances in nanoparticle drug delivery for tumor targeting hold tremendous promise for revolutionizing cancer therapy. While challenges remain in terms of scalability, manufacturing, long-term safety, and regulatory approval, ongoing research and collaboration between scientists, clinicians, and industry stakeholders are likely to unlock the full potential of nanoparticles in transforming cancer treatment and improving patient outcomes. Further research and innovations are likely to address these issues and further improve the effectiveness of nanoparticle-based cancer treatments.

References:

1. Franco, Pablo Igor Ribeiro, et al. "Tumor microenvironment components: Allies of cancer progression." *Pathology-Research and Practice* 216.1 (2020): 152729.

2. Narang, Ajit S., and Sailesh Varia. "Role of tumor vascular architecture in drug delivery." *Advanced drug delivery reviews* 63.8 (2011): 640-658.

3. Dang, Yu, and Jianjun Guan. "Nanoparticle-based drug delivery systems for cancer therapy." *Smart Materials in Medicine* 1 (2020): 10-19.

4. 5. Sethi, Manish, et al. "Effect of drug release kinetics on nanoparticle therapeutic efficacy and toxicity." *Nanoscale* 6.4 (2014): 2321-2327.

5. Wu, Han-Chung, and De-Kuan Chang. "Peptide-mediated liposomal drug delivery system targeting tumor blood vessels in anticancer therapy." *Journal of oncology* 2010 (2010).
6. Masood, Farha. "Polymeric nanoparticles for targeted drug delivery systems for cancer therapy." *Materials Science and Engineering: C* 60 (2016): 569-578.
7. Li, Xuebing, Junda Liu, and Neng Qiu. "Cyclodextrin-Based Polymeric Drug Delivery Systems for Cancer Therapy." *Polymers* 15.6 (2023): 1400.
8. Desai, Neha, et al. "Metallic nanoparticles as drug delivery system for the treatment of cancer." *Expert opinion on drug delivery* 18.9 (2021): 1261-1290.
9. Hossen, Sarwar, et al. "Smart nanocarrier-based drug delivery systems for cancer therapy and toxicity studies: A review." *Journal of advanced research* 15 (2019): 1-18.
10. Desai, Neha, et al. "Metallic nanoparticles as drug delivery system for the treatment of cancer." *Expert opinion on drug delivery* 18.9 (2021): 1261-1290.
11. Yao, Y., Zhou, Y., Liu, L., Xu, Y., Chen, Q., Wang, Y., ... & Shao, A. (2020). Nanoparticle-based drug delivery in cancer therapy and its role in overcoming drug resistance. Frontiers in molecular biosciences, 7, 193.
12. Shi, L., Zhang, J., Zhao, M., Tang, S., Cheng, X., Zhang, W., ... & Wang, Q. (2021). Effects of polyethylene glycol on the surface of nanoparticles for targeted drug delivery. Nanoscale, 13(24), 10748-10764.
13. Raj, S., Khurana, S., Choudhari, R., Kesari, K. K., Kamal, M. A., Garg, N., ... & Kumar, D. (2021, February). Specific targeting cancer cells with nanoparticles and drug delivery in cancer therapy. In Seminars in cancer biology (Vol. 69, pp. 166-177). Academic Press.

14. Siddique, S., & Chow, J. C. (2020). Gold nanoparticles for drug delivery and cancer therapy. Applied Sciences, 10(11), 3824.

15. Aghebati-Maleki, A., Dolati, S., Ahmadi, M., Baghbanzhadeh, A., Asadi, M., Fotouhi, A., ... & Aghebati-Maleki, L. (2020). Nanoparticles and cancer therapy: Perspectives for application of nanoparticles in the treatment of cancers. Journal of cellular physiology, 235(3), 1962-1972.

16. Yan, L., Shen, J., Wang, J., Yang, X., Dong, S., & Lu, S. (2020). Nanoparticle-based drug delivery system: a patient-friendly chemotherapy for oncology. Dose-Response, 18(3), 1559325820936161.

17. Lim, S., Park, J., Shim, M. K., Um, W., Yoon, H. Y., Ryu, J. H., ... & Kim, K. (2019). Recent advances and challenges of repurposing nanoparticle-based drug delivery systems to enhance cancer immunotherapy. Theranostics, 9(25), 7906.

18. Palanikumar, L., Al-Hosani, S., Kalmouni, M., Nguyen, V. P., Ali, L., Pasricha, R., ... & Magzoub, M. (2020). pH-responsive high stability polymeric nanoparticles for targeted delivery of anticancer therapeutics. Communications biology, 3(1), 95.

19. Chandrakala, V., Aruna, V., & Angajala, G. (2022). Review on metal nanoparticles as nanocarriers: Current challenges and perspectives in drug delivery systems. Emergent Materials, 5(6), 1593-1615.
20. Ferraris, C., Cavalli, R., Panciani, P. P., & Battaglia, L. (2020). Overcoming the blood–brain barrier: successes and challenges in developing nanoparticle-mediated drug delivery systems for the treatment of brain tumours. International journal of nanomedicine, 2999-3022.

21. Begines, B., Ortiz, T., Pérez-Aranda, M., Martínez, G., Merinero, M., Argüelles-Arias, F., & Alcudia, A. (2020). Polymeric nanoparticles for drug delivery: Recent developments and future prospects. Nanomaterials, 10(7), 1403.

22. Farzin, A., Etesami, S. A., Quint, J., Memic, A., & Tamayol, A. (2020). Magnetic nanoparticles in cancer therapy and diagnosis. Advanced healthcare materials, 9(9), 1901058.

23. Sun, T., Zhang, Y. S., Pang, B., Hyun, D. C., Yang, M., & Xia, Y. (2021). Engineered nanoparticles for drug delivery in cancer therapy. Nanomaterials and Neoplasms, 31-142.

24. Liu, Z., Robinson, J. T., Tabakman, S. M., Yang, K., & Dai, H. (2011). Carbon materials for drug delivery & cancer therapy. Materials today, 14(7-8), 316-323.

25. Bahrami, B., Hojjat-Farsangi, M., Mohammadi, H., Anvari, E., Ghalamfarsa, G., Yousefi, M., & Jadidi-Niaragh, F. (2017). Nanoparticles and targeted drug delivery in cancer therapy. Immunology letters, 190, 64-83.

26. Khodabandehloo, H., Zahednasab, H., & Hafez, A. A. (2016). Nanocarriers usage for drug delivery in cancer therapy. Iranian journal of cancer prevention, 9(2).

27. Firer, M. A., & Gellerman, G. (2012). Targeted drug delivery for cancer therapy: the other side of antibodies. Journal of hematology & oncology, 5(1), 1-16.